{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "ABBVIE INC.  DL-,01", "longName": "AbbVie Inc.", "messageBoardId": "finmb_141885706", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 133.8, "averageDailyVolume3Month": 278, "averageDailyVolume10Day": 378, "fiftyTwoWeekLowChange": 5.300003, "fiftyTwoWeekLowChangePercent": 0.040769253, "fiftyTwoWeekRange": "130.0 - 159.0", "fiftyTwoWeekHighChange": -23.699997, "fiftyTwoWeekHighChangePercent": -0.14905658, "fiftyTwoWeekLow": 130.0, "fiftyTwoWeekHigh": 159.0, "earningsTimestamp": 1682600400, "earningsTimestampStart": 1690461000, "earningsTimestampEnd": 1690806600, "trailingAnnualDividendRate": 5.78, "trailingPE": 35.14286, "trailingAnnualDividendYield": 0.043037977, "epsTrailingTwelveMonths": 3.85, "epsForward": 13.97, "epsCurrentYear": 12.62, "priceEpsCurrentYear": 10.721078, "sharesOutstanding": 1764290048, "bookValue": 7.525, "fiftyDayAverage": 143.4776, "fiftyDayAverageChange": -8.177597, "fiftyDayAverageChangePercent": -0.056995634, "twoHundredDayAverage": 144.4514, "twoHundredDayAverageChange": -9.151398, "twoHundredDayAverageChangePercent": -0.06335278, "marketCap": 238708441088, "forwardPE": 9.6850395, "priceToBook": 17.980066, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 0.7446016, "regularMarketPrice": 135.3, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1356937200000, "priceHint": 2, "regularMarketChange": 1.0, "regularMarketTime": 1683887286, "regularMarketDayHigh": 135.3, "regularMarketDayRange": "133.8 - 135.3", "regularMarketDayLow": 133.8, "regularMarketVolume": 17, "regularMarketPreviousClose": 134.3, "bid": 134.6, "ask": 135.2, "bidSize": 600, "askSize": 600, "symbol": "4AB.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 68, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 6948244, "fmt": "6.95M", "longFmt": "6,948,244"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43528872, "fmt": "43.53M", "longFmt": "43,528,872"}}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 52, "title": "Vice Chairman & Pres", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 3998042, "fmt": "4M", "longFmt": "3,998,042"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 13150419, "fmt": "13.15M", "longFmt": "13,150,419"}}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 54, "title": "Exec. VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2972736, "fmt": "2.97M", "longFmt": "2,972,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5172329, "fmt": "5.17M", "longFmt": "5,172,329"}}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 59, "title": "Exec. VP of Operations", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2576755, "fmt": "2.58M", "longFmt": "2,576,755"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 28534760, "fmt": "28.53M", "longFmt": "28,534,760"}}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 53, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2983231, "fmt": "2.98M", "longFmt": "2,983,231"}, "exercisedValue": {"raw": 2777988, "fmt": "2.78M", "longFmt": "2,777,988"}, "unexercisedValue": {"raw": 10864175, "fmt": "10.86M", "longFmt": "10,864,175"}}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 60, "title": "Sr. VP of R&D and Chief Scientific Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 56, "title": "Exec. VP & Chief HR Officer", "yearBorn": 1966, "fiscalYear": 2013, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Carrie C. Strom", "age": 44, "title": "Sr. VP of AbbVie & Pres of Global Allergan Aesthetics", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rae L. Livingston", "title": "Chief Equity Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}